Achim H Krauss from Collegeville, PA, age 66

Resumes

Founder And Chief Executive Officer

view source

Location:

10 Toulon Ave, Foothill Ranch, CA 92610

Industry:

Pharmaceuticals

Work:

GlaxoSmithKline since May 2009
Director Biology
Pfizer Mar 2004 - May 2009
Research Fellow
Allergan Sep 1988 - Feb 2004
Principal Scientist

Education:

University of Tübingen 1984 - 1988
Doctorates, Doctor of Philosophy, Philosophy University of Tübingen 1979 - 1984
Bachelors, Bachelor of Science, Pharmacy

Skills:

Pharmaceutical Industry
Drug Discovery
Drug Development
Clinical Development
Biotechnology
Life Sciences
Clinical Trials
Pharmacology
Biopharmaceuticals
Clinical Research
Technology Transfer
Cro
R&D
Ophthalmology
Glp
Lifesciences
Gcp
Medical Devices
Oncology
Immunology
Pharmaceutics
Fda
Regulatory Submissions
Cro Management
Medical Writing
Biomarkers
Research and Development
Sop
Regulatory Affairs
Pharmacokinetics
Strategy
Formulation
Cross Functional Team Leadership

Interests:

Children
Health

Languages:

German
English
French

Us Patents

Ocular Hypotensive Lipids
view source
US Patent:

6395787, May 28, 2002
Filed:

Feb 8, 2000
Appl. No.:

09/500142
Inventors:

David F. Woodward - Lake Forest CA
Helen H. Usansky - Irvine CA
Steven W. Andrews - Rancho Santa Margarita CA
Robert M. Burk - Laguna Beach CA
June Chen - San Juan Capistrano CA
Achim H-P. Krauss - Foothill Ranch CA
Assignee:

Allergan Sales, Inc. - Irvine CA
International Classification:

A61K 315575
US Classification:

514613, 514622, 564171, 564189
Abstract:

Compounds of Formula 1, where the symbols are as defined in the specification, are useful as ocular hypotensive agents but do not exert their activity through the FP prostaglandin receptor. In particular the compound PGF 1-ethanolamide, having the formula was discovered to be present in mammalian tissue as a naturally occurring substance, was synthesized in a substantially pure form and was found to be effective for lowering intraocular pressure in the mammalian eye, but not acting through the FP receptor through which many ocular hypotensive prostaglandins act.

Thromboxane Ligands Without Blood Clotting Side Effects
view source
US Patent:

6462077, Oct 8, 2002
Filed:

Jul 5, 2001
Appl. No.:

09/899713
Inventors:

Robert M. Burk - Laguna Beach CA
Achim H-P Krauss - Foothill Ranch CA
David F. Woodward - Lake Forest CA
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

C07D30793
US Classification:

514469, 549463
Abstract:

A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I, wherein Y is (CH ) ; Z is selected from the group consisting of O, OCH , and (CR ) , x is an integer of 1 or 2; n is 0 or 1; R is hydrogen or an alkyl radical of from 1 to 4 carbons; A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups or said alkylene or alkenylene may have one or more enchained oxa or imino radicals; B is a methyl radical or a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms, or substituted derivatives of said methyl, cycloalkyl or aryl radicals wherein said substituent is selected from the group consisting of halo, nitro, amino, thiol, hydroxy, alkyloxy and alkylcarboxy; and X is selected from the group consisting of nitro, cyano, âCOOR, âCH OR , âC(O)N(R ) , âCH N(R ) âCH NâOH and âCH SR radicals wherein R is a C to C alkyl, phenyl or benzyl and R is R or hydrogen; or a pharmaceutically acceptable salt thereof.

Methods Of Identifying Ocular Hypotensive Compounds Having Reduced Hyperpigmentation
view source
US Patent:

6713268, Mar 30, 2004
Filed:

Jun 26, 2001
Appl. No.:

09/893159
Inventors:

David F. Woodward - Lake Forest CA
Licheng Shi - Irvine CA
Achim H-P Krauss - Foothill Ranch CA
Clayton S. Spada - Fullerton CA
Sheila Mac Neil - Sheffield, GB
Linda C. Smith-Thomas - Sheffield, GB
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

G01N 3353
US Classification:

435 72, 435357, 435 63, 554117, 549422
Abstract:

Methods to identify agents having ocular hypotensive activity which have reduced or absent ability to stimulate iridial hyperpigmentation are disclosed. The methods reside in part in detecting the ability of a test compound to interact with the FP receptor.

Thromboxane Ligands Without Blood Clotting Side Effects
view source
US Patent:

6818779, Nov 16, 2004
Filed:

Aug 5, 2002
Appl. No.:

10/213190
Inventors:

Robert M. Burk - Laguna Beach CA
Achim H-P Krauss - Foothill Ranch CA
David F. Woodward - Lake Forest CA
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

C07D30700
US Classification:

549228, 549397, 549463, 568820
Abstract:

A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I, wherein Y is (CH ) ; Z is selected from the group consisting of x is an integer of 1 or 2; n is 0 or 1; R is hydrogen or an alkyl radical of from 1 to 4 carbons; A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups or said alkylene or alkenylene may have one or more enchained oxa or imino radicals; B is a methyl radical or a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms, or substituted derivatives of said methyl, cycloalkyl or aryl radicals wherein said substituent is selected from the group consisting of halo, nitro, amino, thiol, hydroxy, alkyloxy and alkylcarboxy; and X is selected from the group consisting of nitro, cyano, âCOOR, âCH OR , âC(O)N(R ) , âCH N(R ) âCH NâOH and âCH SR radicals wherein R is a C to C alkyl, phenyl or benzyl and R is R or hydrogen; or a pharmaceutically acceptable salt thereof.

Ep4 Agonists As Agents For Lowering Intraocular Pressure
view source
US Patent:

6956057, Oct 18, 2005
Filed:

Sep 26, 2003
Appl. No.:

10/672499
Inventors:

David F. Woodward - Lake Forest CA, US
Achim H. Krauss - Foothill Ranch CA, US
Robert M. Burk - Laguna Beach CA, US
Mark Holoboski - Laguna Niguel CA, US
Mari F. Posner - Laguna Niguel CA, US
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

A61K031/215
US Classification:

514530, 514573, 514913
Abstract:

The present invention provides a method of treating ocular hypertension or glaucoma which comprises administering to an animal having ocular hypertension or glaucoma therapeutically effective amount of a compound which is a EPagonist.

Thromboxane Ligands Without Blood Clotting Side Effects
view source
US Patent:

7019149, Mar 28, 2006
Filed:

Sep 17, 2004
Appl. No.:

10/943549
Inventors:

Robert M. Burk - Laguna Beach CA, US
Achim H-P Krauss - Foothill Ranch CA, US
David F. Woodward - Lake Forest CA, US
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

C07D 307/00
C07D 311/00
C07D 321/02
US Classification:

549228, 549397, 549463, 560116, 560120, 564138, 564454
Abstract:

A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I, wherein Y is (CH); Z is selected from the group consisting of and (CR), x is an integer of 1 or 2; n is 0 or 1; Ris hydrogen or an alkyl radical of from 1 to 4 carbons; A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups or said alkylene or alkenylene may have one or more enchained oxa or imino radicals; B is a methyl radical or a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms, or substituted derivatives of said methyl, cycloalkyl or aryl radicals wherein said substituent is selected from the group consisting of halo, nitro, amino, thiol, hydroxy, alkyloxy and alkylcarboxy; and X is selected from the group consisting of nitro, cyano, —COOR, —CHOR, —C(O)N(R), —CHN(R)—CH═N—OH and —CHSRradicals wherein R is a Cto Calkyl, phenyl or benzyl and Ris R or hydrogen; or a pharmaceutically acceptable salt thereof.

Prostamide Receptor Antagonists
view source
US Patent:

7045634, May 16, 2006
Filed:

Jul 16, 2004
Appl. No.:

10/893054
Inventors:

Achim H. Krauss - San Marcos CA, US
David F. Woodward - Lake Forest CA, US
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

C07D 236/32
US Classification:

548236
Abstract:

The present invention provides prostamide receptor antagonist compounds that may be represented by the general formula I.

Method For Imparting Artificial Tan To Human Skin
view source
US Patent:

7070768, Jul 4, 2006
Filed:

Sep 25, 2003
Appl. No.:

10/672966
Inventors:

Achim H. Krauss - Foothill Ranch CA, US
Assignee:

Allergan, Inc. - Irvine CA
International Classification:

A61Q 17/04
A61Q 19/00
A61K 8/00
US Classification:

424 59, 424 60, 424400, 424401
Abstract:

The present invention relates to novel pharmaceutical compositions of bimatoprost and other cyclopentane(ene) heptan(en)oic acid amides and their use in preventing sunburn and/or providing an artificial tan to human skin.